MedTrace Logo

A Study of TFX05-01 in Patients With Advanced Solid Tumors

NCT05434299 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-03-16

No results posted yet for this study

Summary

This is an open-label, non-randomized, multicenter, Phase Ⅰ/Ⅱa study to evaluate the safety, tolerability, pharmacokinetics and efficacy of TFX05-01 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

TFX05-01

TFX05-01 for intravenous

Sponsors & Collaborators

  • Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi · Cancer Hospital, Chinese Academy of Medical Sciences，study principal investigator

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-05
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05434299 on ClinicalTrials.gov